HLX48 / Fosun Pharma - LARVOL DELTA

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Shanghai Henlius Biotech

First-in-human • New P1 trial • Hepatocellular Cancer • Oncology • Solid Tumor • EGFR • MET